Drug · DIN 02432730
FLUZONE QUADRIVALENT
5 ML CONTAINS PRESERVATIVE, MULTIDOSE VIAL
Authorized, but not sold for a year or more
Authorized, but the company reports it has not been sold in Canada for at least 12 months.
Status Dormant since March 13, 2026; first marketed September 14, 2015.
- Drug Identification Number (DIN)
- 02432730
- Company (DIN owner)
- Sanofi Vaccines Canada Ltd.Toronto, Ontario, Canada
- Schedule
- Schedule D
- Dosage form
- Suspension
- Route
- Intramuscular
- Therapeutic class (ATC)
- Influenza, inactivated, split virus or surface antigen J07BB02
- Class
- Human
- Record last updated
- August 25, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| HAEMAGGLUTININ-STRAIN A (H1N1) | 30 MCG | ML |
| HAEMAGGLUTININ-STRAIN A (H3N2) | 30 MCG | ML |
| HAEMAGGLUTININ-STRAIN B (VICTORIA) | 30 MCG | ML |
| HAEMAGGLUTININ-STRAIN B (YAMAGATA) | 30 MCG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 10, 2017: NOC 18953New Drug Submission (NDS) · Transfer of drug identification numbers
- October 17, 2014: NOC 16217Supplement to a New Drug Submission (SNDS) · New presentation - multidose vial
Other DINs named FLUZONE QUADRIVALENT
- DIN 02420635 · Cancelled Pre Market
- DIN 02420643 · Dormant
- DIN 02420651 · Cancelled Pre Market